查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1717856

局部性节段性肾小球硬化症市场：按药物类别、分期、最终用户和患者类型划分 - 2025-2030 年全球预测

Focal Segmental Glomerulosclerosis Market by Drug Class, Stage, End-Use, Patient Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

局部节段性肾小球硬化症市场规模预计在 2024 年达到 19.8 亿美元，预计在 2025 年达到 21.3 亿美元，预计在 2030 年达到 31.3 亿美元，复合年增长率为 7.87%。

局部性节段性肾丝球硬化症市场：简介

主要市场统计数据
基准年2024年 19.8亿美元
预计2025年 21.3亿美元
预测年份 2030 31.3亿美元
复合年增长率（%） 7.87%

这份全面的概述以分析的视角深入探讨了局部节段性肾小球硬化症 (FSGS) 的多面世界，揭示了影响这一重要治疗领域的市场动态。 FSGS 是一种肾臟疾病，其疤痕会对肾臟的过滤系统造成不可逆的损害。诊断过程和治疗策略的最新进展极大地改变了市场焦点。本介绍概述了透过深入了解患者需求和医疗保健提供者挑战来实现临床创新的环境。研发和行业专家都观察到越来越多的证据强调了开发更有效治疗通讯协定的迫切需求。医疗技术和监管环境的不断发展以及新的科学突破为市场成长创造了坚实的基础。相关人员正在越来越多地探索使用新的药物疗法和诊断方法来满足成人和儿科患者未满足的需求。本次介绍性讨论将进一步探讨先进调查方法的整合，这些方法正在彻底改变病患照护策略并为治疗模式创造新的可能性。对临床研究卓越性和基于证据的决策的持续承诺增强了 FSGS 领域的市场发展潜力。

改变局部节段性肾丝球硬化症市场

由于创新治疗方法的融合、增强的诊断工具和不断发展的监管环境，局部节段性肾小球硬化症的治疗格局正在转变。近年来，人们对传统治疗方法进行了重新评估，以提供更有针对性和更有效的治疗。先驱研究挑战了既定的范式，并促成了支持早期诊断和个人化治疗方法的尖端技术的整合。从传统管理转向精准医疗为中心的方法的转变是显而易见的。目前，越来越多的临床试验致力于减缓肾丝球瘢痕的进展，同时改善多个人群患者的生活品质。同时，研发投资正在推动新型药物和介入技术的发展。临床、技术和分子生物学的进步不仅有助于完善现有的治疗通讯协定，而且还推动产业策略探索新的领域。科学发现与市场应用之间不断加强的相互作用代表着医疗保健领域的关键时刻，为解决 FSGS 管理中长期存在和新兴挑战的下一代解决方案铺平了道路。

推动市场成长的关键细分洞察

对市场细分的详细分析揭示了清晰的细分因素，有助于整个 FSGS 治疗整体的策略决策。透过药物类别分析可以确定主要的治疗选择，包括血管收缩素酶抑制剂、血管收缩素受体阻断剂和皮质类固醇，每种药物在控制疾病方面都发挥重要作用。透过对疾病阶段的深刻洞察，市场进一步分为原发性类别和次发性类别。这种区分为相关人员提供了对治疗时机和介入措施优先顺序的细緻理解。此外，比较最终用途设定时，市场动态差异很大。诊所和医院需要不同的基础设施并有不同的病患照护模式。细分的另一个方面是患者类型，成人和儿童族群之间存在差异。这些见解源自于药理功效、临床结果和经济因素的结合，清楚地表明了每个细分观点如何有助于全面了解市场。这些不同但又相互关联的领域的融合正在创造一个面向个人化医疗和有针对性的治疗创新的竞争日益激烈的格局。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 提高医护人员的盛行率和疾病意识
      • 扩大医疗保健基础设施并改善患者进入专科肾臟中心的机会
      • 肾臟疾病创新与个人化治疗方法研发投资激增
    • 限制因素
      • 严格的监管障碍阻碍了药品核准
    • 机会
      • 透过整合基因治疗和生物标记主导策略设计创新治疗方法
      • 开发先进的诊断和影像解决方案，实现早期发现和精准治疗
    • 任务
      • 潜在的安全风险和副作用限制了广泛采用
  • 市场区隔分析
    • 药物类别：血管收缩素酶抑制剂越来越受到人们的青睐，用于减少蛋白尿和保护肾功能
    • 最终用途：扩大 FSGS 在医院的应用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 局部节段性肾丝球硬化症市场（依药物类别）

  • 血管收缩素酶抑制剂
  • 血管收缩素素受体阻断剂
  • 皮质类固醇

7. 局部节段性肾丝球硬化症市场（依阶段）

  • 基本的
  • 次要

8. 局部节段性肾丝球硬化症市场（依最终用途）

  • 诊所
  • 医院

9. 局部节段性肾丝球硬化症市场（依病患类型）

  • 成人
  • 小儿科

10. 美洲局部节段性肾丝球颤动症市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太地区局部肾丝球硬化症市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲局部节段性肾丝球硬化症市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Alkem Laboratories Ltd.
  • Bristol Myers Squibb Company
  • Certa Therapeutics Pty Ltd.
  • Cipla Ltd.
  • CMG Biotech Pvt. Ltd.
  • Dr Reddy's Laboratories Ltd.
  • Fresenius Kabi Pvt. Ltd.
  • GSK PLC
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer, Inc.
  • Sanofi SA
  • Travere Therapeutics, Inc.
  • Vera Therapeutics Inc.
Product Code: MRR-C002B1C994EF

The Focal Segmental Glomerulosclerosis Market was valued at USD 1.98 billion in 2024 and is projected to grow to USD 2.13 billion in 2025, with a CAGR of 7.87%, reaching USD 3.13 billion by 2030.

Focal Segmental Glomerulosclerosis Market: A Comprehensive Introduction

KEY MARKET STATISTICS
Base Year [2024] USD 1.98 billion
Estimated Year [2025] USD 2.13 billion
Forecast Year [2030] USD 3.13 billion
CAGR (%) 7.87%

In this comprehensive overview, we delve into the multifaceted world of Focal Segmental Glomerulosclerosis (FSGS) with an analytical lens that uncovers the market dynamics shaping this critical therapeutic area. FSGS represents a form of kidney disease where scarring causes irreversible damage to the kidney's filtering units. Recent advances in both diagnostic processes and therapeutic strategies have resulted in significant shifts in market focus. This introduction sets the stage by outlining an environment where clinical innovation is matched with a deep understanding of patient needs and healthcare provider challenges. Researchers and industry experts alike have observed a growing body of evidence that underscores the urgency of developing more effective treatment protocols. Alongside emerging scientific breakthroughs, the relentless evolution in medical technology and regulatory landscapes has created a robust platform for market growth. Stakeholders are increasingly looking to leverage novel drug therapies and diagnostic approaches to address the unmet needs of both adult and pediatric patients. This introductory discussion further explores the integration of advanced research methodologies, which are revolutionizing patient care strategies and catalyzing new opportunities in treatment paradigms. The ongoing commitment to excellence in clinical research and evidence-based decision-making reinforces the potential for transformative market developments in the field of FSGS.

Transformative Shifts in the Healthcare Landscape

The landscape of Focal Segmental Glomerulosclerosis treatment is undergoing transformative shifts driven by a confluence of innovative therapies, enhanced diagnostic tools, and evolving regulatory frameworks. Recent years have witnessed a marked change as traditional treatment modalities are being re-evaluated in favor of approaches that provide targeted and effective patient outcomes. Pioneering research has challenged established paradigms, leading to the integration of advanced technologies that support earlier diagnosis and personalized treatment regimens. There is a clear transition from conventional management to approaches that emphasize precision medicine. An increasing number of clinical trials now focus on reducing the progression of glomerular scarring while improving patient quality of life across diverse demographics. In parallel, investments in research and development are fostering the growth of novel drug classes and intervention techniques. This combination of clinical, technological, and molecular advancements serves to not only refine existing treatment protocols but also to propel industry strategies towards exploring new frontiers. The evolving interplay between scientific discovery and market application signifies a pivotal moment in healthcare, paving the way for next-generation solutions that can address both longstanding and emerging challenges in FSGS management.

Critical Segmentation Insights Driving Market Growth

A granular breakdown of the market reveals distinct segmentation factors that inform strategic decision-making across the FSGS treatment continuum. Analysis based on drug class identifies key therapeutic options, spanning from angiotensin enzyme inhibitors to angiotensin receptor blockers and extending to corticosteroids, each of which plays a critical role in managing the disease. Insightful considerations regarding disease stage further divide the market into primary and secondary categories; this differentiation provides stakeholders with a nuanced understanding of treatment timing and intervention priorities. Moreover, market dynamics differ substantially when comparing end-use settings. The requirements and capabilities of clinics versus hospitals highlight varying infrastructure needs and patient care models. Another dimension of segmentation targets the patient type, with differences emerging between adult and pediatric populations. These insights, drawn from a combination of pharmacological efficacy, clinical outcomes, and economic factors, underscore how each segmentation perspective contributes to a comprehensive market understanding. The convergence of these distinct yet interrelated segments underpins a competitive landscape that is increasingly oriented towards personalized care and targeted therapeutic innovation.

Based on Drug Class, market is studied across Angiotensin Enzyme Inhibitors, Angiotensin Receptor Blockers, and Corticosteroids.

Based on Stage, market is studied across Primary and Secondary.

Based on End-Use, market is studied across Clinics and Hospitals.

Based on Patient Type, market is studied across Adults and Pediatric.

Regional Trends Shaping Forecast and Opportunities

Regional dynamics play a pivotal role in shaping market trends and highlighting areas of opportunity for new therapeutic approaches in FSGS. In the Americas, established healthcare frameworks are coupled with substantial investments in research and development, fostering a robust environment for innovative treatment strategies. The dynamics in Europe, Middle East, and Africa further enrich this perspective, where varying regulatory landscapes and heterogeneous healthcare infrastructures necessitate tailored market strategies. Diverse economic environments and evolving patient care models in these regions pave the way for multifaceted growth opportunities. In the Asia-Pacific region, rapid advancements in healthcare infrastructure and an increasing focus on early detection techniques have fuelled a surge in demand for effective FSGS treatment solutions. The interplay of strong governmental support in certain markets with the pursuit of cutting-edge medical technology across these regions drives competitive differentiation and strategic localization. This regional analysis provides a thorough understanding of how local factors influence the adoption of new treatment paradigms and the allocation of healthcare resources, thereby steering the overall trajectory of the market.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Shaping the Market's Future

A detailed examination of key company players reveals an intricate network of innovation and strategic market positioning in the FSGS landscape. Industry frontrunners from diverse geographical locations are focusing on advancing therapeutic options and optimizing patient care by harnessing research and development capabilities. Leading entities such as Alkem Laboratories Ltd. and Bristol Myers Squibb push the envelope in clinical research, while companies like Certa Therapeutics Pty Ltd. and Cipla Ltd. continue to invest in technologies that improve diagnostic accuracy and treatment delivery. Other significant contributors, including CMG Biotech Pvt. Ltd. and Dr Reddy's Laboratories Ltd., have demonstrated a balanced approach, integrating cost-effective therapies with high-quality care solutions. Fresenius Kabi Pvt. Ltd. and GSK PLC further emphasize the value of global outreach and strategic research collaborations. The active involvement of Hikma Pharmaceuticals PLC and Intas Pharmaceuticals Ltd. showcases a blend of established market practices with innovative strategies that are poised to capture emerging market segments. Alongside other key players such as Lupin Ltd., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer, Inc., Sanofi S.A., Travere Therapeutics, Inc., and Vera Therapeutics Inc., there is a consistent drive towards the development of therapies that are responsive to both clinical and economic challenges, thereby positioning the market for sustained future growth.

The report delves into recent significant developments in the Focal Segmental Glomerulosclerosis Market, highlighting leading vendors and their innovative profiles. These include Alkem Laboratories Ltd., Bristol Myers Squibb Company, Certa Therapeutics Pty Ltd., Cipla Ltd., CMG Biotech Pvt. Ltd., Dr Reddy's Laboratories Ltd., Fresenius Kabi Pvt. Ltd., GSK PLC, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer, Inc., Sanofi S.A., Travere Therapeutics, Inc., and Vera Therapeutics Inc.. Strategic Recommendations for Market Leaders

Industry leaders are encouraged to adopt strategic and innovative recommendations to harness future opportunities within the FSGS market. It is imperative to prioritize investments in research and development that not only target the improvement of existing drug regimens but also pioneer novel therapeutic agents tailored to the disease's underlying mechanisms. Leveraging digital transformation and data analytics will provide enhanced patient segmentation and more precise treatment personalization. Leaders are advised to engage in cross-disciplinary collaborations that integrate advanced diagnostic technologies, quality clinical trial initiatives, and real-world evidence to support robust clinical claims. Additionally, exploring partnerships with academic institutions and biotech firms can inject fresh perspectives and expedite the pipeline of emerging treatments. Emphasizing regulatory compliance and safety will further reinforce market credibility while enabling quicker access to critical markets. By aligning strategic decision-making with evolving patient needs and market trends, organizations can navigate the complexities of healthcare systems more effectively. These actionable recommendations offer a framework for optimizing product portfolios, minimizing risks through early intervention in clinical stages, and ultimately enhancing competitive positioning in a rapidly advancing therapeutic landscape.

Conclusion and Market Outlook

In conclusion, the dynamic landscape of Focal Segmental Glomerulosclerosis treatment presents both significant opportunities and multifaceted challenges. This analysis has underscored the need for a deeply integrated approach encompassing innovative research, segmented market insights, and robust regional strategies. As stakeholders continue to adapt to the transformative shifts in diagnostic and therapeutic methodologies, the path forward is defined by strategic collaboration, targeted investment in breakthrough research, and enhanced patient care initiatives. The synthesis of detailed segmentation insights, regional trends, and leading company strategies not only affirms the potential for growth but also highlights the critical areas that demand immediate attention. It is clear that the evolving market requires a balanced blend of forward-thinking policies and rigorous clinical investigation. With an emphasis on precision medicine and sustainable market practices, the current trajectory is set to redefine how healthcare providers manage FSGS. This consolidated examination therefore serves as a roadmap, guiding decision-makers towards market strategies that are both innovative and clinically effective.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence and enhanced disease awareness among healthcare providers
      • 5.1.1.2. Expansion of healthcare infrastructure and improved patient access to specialized nephrology centers
      • 5.1.1.3. Surge in investments in research and development for innovative treatment approaches and personalized therapies for kidney disorders
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory hurdles delaying drug approvals
    • 5.1.3. Opportunities
      • 5.1.3.1. Designing innovative therapeutic approaches integrating gene therapy and biomarker-driven strategies
      • 5.1.3.2. Development of advanced diagnostic and imaging solutions for early detection and precision treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Potential safety risks and adverse side limiting widespread adoption
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Increasing preference for angiotensin enzyme inhibitors for reducing proteinuria and maintaining kidney function
    • 5.2.2. End Use: Expanding utilization of FSGS in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Focal Segmental Glomerulosclerosis Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Angiotensin Enzyme Inhibitors
  • 6.3. Angiotensin Receptor Blockers
  • 6.4. Corticosteroids

7. Focal Segmental Glomerulosclerosis Market, by Stage

  • 7.1. Introduction
  • 7.2. Primary
  • 7.3. Secondary

8. Focal Segmental Glomerulosclerosis Market, by End-Use

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals

9. Focal Segmental Glomerulosclerosis Market, by Patient Type

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Pediatric

10. Americas Focal Segmental Glomerulosclerosis Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Focal Segmental Glomerulosclerosis Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Focal Segmental Glomerulosclerosis Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Travere Therapeutics to submit NDA for FILSPARI (sparsentan) in FSGS
    • 13.3.2. Certa Therapeutics acquired OccuRx to expand GPR68 platform
    • 13.3.3. Vera Therapeutics partners with the University of Michigan on the NEPTUNE Match
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alkem Laboratories Ltd.
  • 2. Bristol Myers Squibb Company
  • 3. Certa Therapeutics Pty Ltd.
  • 4. Cipla Ltd.
  • 5. CMG Biotech Pvt. Ltd.
  • 6. Dr Reddy's Laboratories Ltd.
  • 7. Fresenius Kabi Pvt. Ltd.
  • 8. GSK PLC
  • 9. Hikma Pharmaceuticals PLC
  • 10. Intas Pharmaceuticals Ltd.
  • 11. Lupin Ltd.
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Otsuka Pharmaceutical Co., Ltd
  • 15. Pfizer, Inc.
  • 16. Sanofi S.A.
  • 17. Travere Therapeutics, Inc.
  • 18. Vera Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET MULTI-CURRENCY
  • FIGURE 2. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET MULTI-LANGUAGE
  • FIGURE 3. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET RESEARCH PROCESS
  • FIGURE 4. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN ENZYME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 189. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2024